title: Costs of intravenous immunoglobulin therapy in patients with unconfirmed parvovirus b19 pure red cell aplasia.
authors.affiliation: Faculty of Medicine, Université Paris Descartes and Department of Internal Medicine, Cochin hospital, Assistance Publique-Hôpitaux de Paris (AP-HP) Commission for the Adequate Prescription of Drugs, AP-HP.
authors.forename: Luc
authors.initials: L
authors.lastname: Mouthon
authors.affiliation: URC Eco Ile de France, AP-HP.
authors.forename: Morgane
authors.initials: M
authors.lastname: Michel
authors.affiliation: URC Eco Ile de France, AP-HP Université Paris Diderot, Sorbonne Paris Cité, ECEVE, UMRS 1123 Inserm, ECEVE, U1123, Paris, France.
authors.forename: Coralie
authors.initials: C
authors.lastname: Gandré
authors.affiliation: Commission for the Adequate Prescription of Drugs, AP-HP.
authors.forename: Catherine
authors.initials: C
authors.lastname: Montagnier-Petrissans
authors.affiliation: URC Eco Ile de France, AP-HP Université Paris Diderot, Sorbonne Paris Cité, ECEVE, UMRS 1123 Inserm, ECEVE, U1123, Paris, France.
authors.forename: Karine
authors.initials: K
authors.lastname: Chevreul
mesh_terms: D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D010322:Parvoviridae Infections / Q000150:complications* / Q000628:therapy*; D016732:Parvovirus B19, Human / Q000302:isolation & purification*; D012010:Red-Cell Aplasia, Pure / Q000628:therapy*
chemical_list: D016756:Immunoglobulins, Intravenous